Heat Stress-InducedPI3K/mTORC2-Dependent AKT signaling is a central mediator of hepatocellular carcinoma survival to thermal ablation induced heat stress

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Thompson, Scott M ^a   Callstrom, Matthew R ^a   Jondal, Danielle E ^a   Butters, Kim A ^a   Knudsen, Bruce E ^a   Anderson, Jill L ^a   Lien, Karen R ^a   Sutor, Shari L ^a   Lee, Ju Seog ^b   Thorgeirsson, Snorri S ^c   Grande, Joseph P ^a   Roberts, Lewis R ^d   Woodrum, David A ^a  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; SELUMETINIB; CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE; MULTIPROTEIN COMPLEX; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL KILLING; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEAT STRESS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOLECULAR MECHANICS; NONHUMAN; RADIOFREQUENCY ABLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL PROLIFERATION; GENETICS; HEAT; HEP-G2 CELL LINE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEP G2 CELLS; HEPATOCYTES; HOT TEMPERATURE; HUMANS; MALE; MULTIPROTEIN COMPLEXES; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84990927869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162634     Document Type: Article

References (75)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, MathersC, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015; 136(5): E359-86. doi: 10.1002/ijc.29210 PMID: 25220842
2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. doi: 10.1136/gutjnl-2013-306627 PMID: 24531850
3. Yang JD, Kim B, SandersonSO, St Sauver JL, Yawn BP, Pedersen RA, et al. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc. 2012; 87(1):9-16. doi: 10.1016/j. mayocp.2011.07.001 PMID: 22212963
4. Yang JD, Roberts LR. Hepatocellular carcinoma:A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. doi: 10.1038/nrgastro.2010.100 PMID: 20628345
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009; 136(4):1134-44. doi: 10.1053/j.gastro.2009.02.038 PMID: 19245868
6. Tiong L, MaddernGJ. Systematic review and meta-Analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011; 98(9):1210-24. doi: 10.1002/bjs.7669 PMID: 21766289
7. Wang JH,Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012; 56(2):412-8. doi: 10.1016/j.jhep.2011.05.020 PMID: 21756858
8. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009; 49(2):453-9. doi: 10.1002/hep.22648 PMID: 19065676
9. Yin XY, Xie XY, Lu MD, Xu HX, Xu ZF, Kuang M, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-termoutcome and prognostic factors. Cancer. 2009; 115 (9):1914-23. doi: 10.1002/cncr.24196 PMID: 19241423
10. Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, et al. Risk factors for long-termprognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol. 2011; 23(6):528-36. doi: 10.1097/MEG.0b013e328346d529 PMID: 21537128
11. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008; 12(1):183-91. PMID: 17874276
12. Yang B, Zou J, Xia J, Ren Z, Gan Y, Wang Y, et al. Risk factors for recurrence of small hepatocellular carcinoma after long-termfollow-up of percutaneous radiofrequency ablation. Eur J Radiol. 2011; 79 (2):196-200. doi: 10.1016/j.ejrad.2010.02.010 PMID: 20303686
13. Angonese C, Baldan A, Cillo U, D'Alessandro A, De Antoni M, De Giorgio M, et al. Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread? Gut. 2006; 55(3):435-6. PMID: 16474113
14. Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology. 2003; 50(54):2179-84. PMID: 14696492
15. Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, et al. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation.World J Gastroenterol. 2004; 10(8):1137-40. PMID: 15069713
16. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterialchemoembolization and percutaneous radiofrequency ablation in the primarytumour region. Eur J Gastroenterol Hepatol. 2001; 13(3):291-4. PMID: 11293452
17. Shiozawa K,Watanabe M, Takahashi M,Wakui N, Iida K, Sumino Y. Analysis of patients with rapid aggressive tumor progression of hepatocellular carcinoma after percutaneous radiofrequency ablation. Hepatogastroenterology. 2009; 56(96):1689-95. PMID: 20214219
18. Kang TW, Lim HK, LeeMW, Kim YS, Rhim H, Lee WJ, et al. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. Radiology. 2015:141215.
19. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2003; 197 (5):759-64. PMID: 14585410
20. Kei SK, Rhim H, Choi D, Lee WJ, Lim HK, Kim YS. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol. 2008; 190(6):1544-51. doi: 10.2214/AJR.07.2798 PMID: 18492905
21. Liu CH, ArellanoRS, Uppot RN, Samir AE, GervaisDA, Mueller PR. Radiofrequency ablation of hepatic tumours: effect of post-Ablation margin on local tumour progression. Eur Radiol. 2010; 20(4):877-85. doi: 10.1007/s00330-009-1610-4 PMID: 19760232
22. MertynaP, DewhirstMW, Halpern E, GoldbergW, Goldberg SN. Radiofrequency ablation: the effect of distance and baseline temperature on thermal dose required for coagulation. Int J Hyperthermia. 2008; 24(7):550-9. doi: 10.1080/02656730802035662 PMID: 18608586
23. MertynaP, Hines-Peralta A, Liu ZJ, Halpern E, GoldbergW, Goldberg SN. Radiofrequency ablation: variability in heat sensitivity in tumors and tissues. J Vasc Interv Radiol. 2007; 18(5):647-54. PMID: 17494847
24. Thompson SM, Callstrom MR, Butters KA, Knudsen B, Grande JP, Roberts LR, et al. Heat stress induced cell death mechanisms in hepatocytes and hepatocellular carcinoma: in vitro and in vivo study. Lasers Surg Med. 2014; 46(4):290-301. doi: 10.1002/lsm.22231 PMID: 24643941
25. Hildebrandt B,Wust P, AhlersO, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002; 43(1):33-56. PMID: 12098606
26. Park HG, Han SI, Oh SY, Kang HS. Cellular responses to mild heat stress. Cell Mol Life Sci. 2005; 62 (1):10-23. PMID: 15619003
27. Ahmed M, Goldberg SN. Basic science research in thermal ablation. Surg Oncol Clin N Am. 2011; 20 (2):237-58, vii. doi: 10.1016/j.soc.2010.11.011 PMID: 21377581
28. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010; 30(1):35-51. doi: 10.1055/s-0030-1247131 PMID: 20175032
29. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12(4):410-6. PMID: 16532004
30. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989-5005. doi: 10.1038/onc.2010.236 PMID: 20639898
31. Dhanasekaran R, Venkatesh SK, Torbenson M, Roberts LR. Clinical Implications of Basic Research in Hepatocellular Carcinoma. J Hepatol. 2016; 64(3):736-45. doi: 10.1016/j.jhep.2015.09.008 PMID: 26450813
32. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40(3):667-76. PMID: 15349906
33. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004; 36(12):1306-11. PMID: 15565109
34. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology. 2008; 47(4):1211-22. doi: 10.1002/hep.22202 PMID: 18318435
35. Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, et al. The transcription factor GLI1 mediates TGFbeta1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One. 2012; 7(11):e49581. doi: 10.1371/journal.pone.0049581 PMID: 23185371
36. Minko T, Kopeckova P, Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not inducemultidrug resistance in a human ovarian carcinoma cell line. J Control Release. 1999; 59 (2):133-48. PMID: 10332049
37. Thompson SM, Callstrom MR, Butters KA, Sutor SL, Knudsen B, Grande JP, et al. Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study. Cardiovasc Intervent Radiol. 2014; 37(5):1343-51. doi: 10.1007/s00270-013-0828-3 PMID: 24452318
38. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005; 23(1):94-101. PMID: 15592455
39. Thompson SM, Callstrom MR, Knudsen B, Anderson JL, CarterRE, Grande JP, et al. Development and Preliminary Testing of a Translational Model of Hepatocellular Carcinoma for MR Imaging and Interventional Oncologic Investigations. J Vasc Interv Radiol. 2012; 23(3):385-95. doi: 10.1016/j.jvir. 2011.11.018 PMID: 22265247
40. Thompson SM, Callstrom MR, Knudsen BE, Anderson JL, Sutor SL, Butters KA, et al. Molecular Bioluminescence Imaging as a Noninvasive Tool for MonitoringTumor Growth and Therapeutic Response to MRI-Guided Laser Ablation in a Rat Model of Hepatocellular Carcinoma. Invest Radiol. 2013; 48 (6):413-21. doi: 10.1097/RLI.0b013e31827a4a3f PMID: 23262791
41. Thompson SM, Callstrom MR, Knudsen B, Anderson JL, Butters KA, Grande JP, et al. AS30D Model of Hepatocellular Carcinoma: Tumorigenicity and Preliminary Characterization by Imaging, Histopathology, and Immunohistochemistry. Cardiovasc Intervent Radiol. 2013; 36(1):198-203. doi: 10.1007/s00270-012-0466-1 PMID: 22923329
42. Joshi CN, Jain SK, MurthyPS. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc. 2004; 13(1):11-7. PMID: 15063836
43. Sapareto SA, Dewey WC. Thermaldose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984; 10(6):787-800. PMID: 6547421
44. Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J. 2000; 19(20):5429-39. PMID: 11032810
45. RobertsPJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-Activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26(22):3291-310. PMID: 17496923
46. Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol. 1997; 17 (1):338-44. PMID: 8972214
47. Sarbassov DD, GuertinDA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. PMID: 15718470
48. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-74. PMID: 17604717
49. AltomareDA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24(50):7455-64. PMID: 16288292
50. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005; 25(2):212-25. PMID: 15918149
51. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011; 7(10):1149-67. doi: 10.2217/fon.11.95 PMID: 21992728
52. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 2005; 103(2):307-12. PMID: 15593087
53. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006; 25(27):3787-800. PMID: 16799620
54. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitisC virus infection. J Hepatol. 2008; 48(1):83-90. PMID: 17998146
55. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91(2):231-41. PMID: 9346240
56. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785-9. PMID: 8524413
57. Zhang Y, Gan B, Liu D, Paik JH. FoxO family members in cancer. Cancer Biol Ther. 2011; 12(4):253-9. PMID: 21613825
58. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7(7):1851-63. doi: 10. 1158/1535-7163.MCT-08-0017 PMID: 18606717
59. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-1 42886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6(1):138-46. PMID: 17237274
60. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. doi: 10.1016/j.cell.2012.03.017PMID: 22500797
61. RobertsPJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, WhittleMC, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithfulmurine cancer models. Clin Cancer Res. 2012; 18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563 PMID: 22872574
62. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res. 2002; 8(6):1957-63. PMID: 12060641
63. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012 PMID: 20571069
64. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996; 58 (5):373-95. PMID: 8594303
65. Field SB, MorrisCC. The relationship between heating time and temperature: its relevance to clinical hyperthermia. Radiother Oncol. 1983; 1(2):179-86. PMID: 6680222
66. SchamhartDH, BerendsenW, van Rijn J, van Wijk R. Comparative studies of heat sensitivity of several rat hepatoma cell lines and hepatocytes in primaryculture. Cancer Res. 1984; 44(10):4507-16. PMID: 6467209
67. Shaw M, Cohen P, Alessi DR. The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-Activated protein kinase-Activated protein kinase-2. Biochem J. 1998; 336 (Pt 1):241-6. PMID: 9806907
68. Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, et al. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Research. 2012; 32 (7):2531-6. PMID: 22753710
69. Yang F, Qian XJ, QinW, Deng R,Wu XQ, Qin J, et al. Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in NasopharyngealCarcinoma. PLoS One. 2013; 8(3):e59879. doi: 10.1371/journal.pone.0059879 PMID: 23533654
70. Kuger S, Graus D, Brendtke R, Gunther N, Katzer A, Lutyj P, et al. Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Transl Oncol. 2013; 6(2):169-79. PMID: 23544169
71. Yang S, Xiao X, Meng X, Leslie KK. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One. 2011; 6(10):e26343. doi: 10.1371/journal.pone.0026343 PMID: 22039466
72. Koseoglu S, Lu Z, Kumar C, KirschmeierP, Zou J. AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biol Ther. 2007; 6(5):755-62. PMID: 17426444
73. Hara S, Nakashiro K, Goda H, Hamakawa H. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun. 2008; 370(1):123-8. doi: 10.1016/j.bbrc.2008.03.042 PMID: 18355439
74. Gonzalez E, McGraw TE. The Akt kinases: isoformspecificity in metabolism and cancer. Cell Cycle. 2009; 8(16):2502-8. PMID: 19597332
75. Sasaki T, Nakashiro K, Tanaka H, Azuma K, Goda H, Hara S, et al. Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2010; 399(1):79-83. doi: 10.1016/j.bbrc.2010.07.045 PMID: 20638364